Diffusion Pharmaceuticals CFO William Hornung departs; separation agreement provides $254K lump sum

CervoMed Inc.

CFO William K. Hornung departed effective May 15, 2023, after serving since September 2018.
Separation benefits include lump-sum of $254,663 (9 months base salary) and pro-rated bonus of $44,014.
Vested stock options remain exercisable for 3 months post-separation.
Health insurance premium reimbursement of $25,388 provided for 12 months.
No successor CFO named; CEO Robert J. Cobuzzi Jr. remains.

item 1.01 item 5.02 item 1.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

William K. Hornung

Chief Financial Officer

CRVO · CervoMed Inc.

Effective: 2023-05-15
Filed: May 19, 2023, 7:59 PM ET

Effective as of the close of business on May 15, 2023, Mr. William K. Hornung departed Diffusion Pharmaceuticals Inc.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

William K. Hornung departed as Chief Financial Officer at CervoMed Inc..

Action: departed
Role: Chief Financial Officer

Exact text from the filing

Effective as of the close of business on May 15, 2023, Mr. William K. Hornung departed Diffusion Pharmaceuticals Inc.

View on SEC.gov

CervoMed Inc. filing history →

Source: SEC EDGAR

accession 0001437749-23-015313

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.